Skip to main content
RELMADA THERAPEUTICS, INC. logo

RELMADA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · RLMD ISIN · US75954H1005 LEI · 549300217EASRZ9JSF81 US Professional, scientific and technical activities
Open in API
Filings indexed 582 across all filing types
Latest filing 2016-09-09 Annual Report
Country US United States of America
Listing US RLMD

About RELMADA THERAPEUTICS, INC.

https://www.relmada.com/

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies. The company's lead program is NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer. The formulation is designed for gradual drug release over 10 days to enhance local exposure and minimize systemic toxicity. Relmada's pipeline also includes Sepranolone, which is being developed for compulsive disorders. Following positive proof-of-concept data in Tourette’s syndrome, the company is planning a Phase 2 study of Sepranolone in Prader-Willi Syndrome, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
ANNUAL REPORT
Annual Report FY 2016
2016-09-09 English
SCHEDULE 13G
Major Shareholding Notification
2016-06-24 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 16, 2016. It details changes in the company's management, specifically an amendment to the CFO's employment agreement and the resignation of the Chief Business Officer. The content focuses on employment agreements, severance terms, and officer departure, which aligns with announcements about changes in the company's board of directors or senior management. There are no financial statements or earnings data, so it is not an earnings release or financial report. The document is not a proxy statement, dividend notice, or other categories. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2016-06-17 English
SCHEDULE 13D/A
Major Shareholding Notification
2016-06-02 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 11, 2016. It announces the appointment of a new Chief Financial Officer and the departure of the previous Vice President of Finance. The content focuses on management changes, including employment agreements, compensation, and severance terms. There are no financial statements or detailed financial performance data included. The primary subject is changes in senior management personnel, which aligns with the Board/Management Information category. Therefore, the document should be classified as MANG (Board/Management Information). The document length (8750 characters) and content confirm it is not a brief announcement or a report publication notice, but a substantive filing about management changes.
2016-05-13 English
QUARTERLY REPORT
Interim / Quarterly Report 9M 2016
2016-05-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.